PRIMARY STUDY

β-Caryophyllene nanoparticles design and development: Controlled drug delivery of cannabinoid CB2 agonist as a strategic tool towards neurodegeneration

Key Findings:  This preclinical test found the nanoparticulation of β-caryophyllene, to target the CB2 receptors in the brain, makes it suitable for intranasal administration, which may present therapeutic delivery options in disorders that require CNS penetration, such as neurodegenerative diseases.